Cargando…
Bone lead, hypertension, and lead nephropathy.
There is considerable clinical evidence that excessive lead absorption causes renal failure with hypertension and predisposes individuals to hypertension even in the absence of detectable renal failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may ref...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474623/ https://www.ncbi.nlm.nih.gov/pubmed/3203647 |
_version_ | 1782127949861879808 |
---|---|
author | Wedeen, R P |
author_facet | Wedeen, R P |
author_sort | Wedeen, R P |
collection | PubMed |
description | There is considerable clinical evidence that excessive lead absorption causes renal failure with hypertension and predisposes individuals to hypertension even in the absence of detectable renal failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may reflect the cause (or contributing cause) of end-stage renal disease in 5% of the European dialysis population. In these patients, bone lead levels were four times higher than in unexposed cadavers (6 micrograms/g wet weight) and approximated levels found in lead workers (30 micrograms/g). At present, the most reliable index of the body lead burden is the CaNa2 EDTA lead mobilization test. In vivo tibial X-ray-induced X-ray fluorescence (XRF) is a more practical noninvasive technique for assessing bone lead, which should find widespread application as a diagnostic tool and for epidemiologic studies. |
format | Text |
id | pubmed-1474623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1988 |
record_format | MEDLINE/PubMed |
spelling | pubmed-14746232006-06-09 Bone lead, hypertension, and lead nephropathy. Wedeen, R P Environ Health Perspect Research Article There is considerable clinical evidence that excessive lead absorption causes renal failure with hypertension and predisposes individuals to hypertension even in the absence of detectable renal failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may reflect the cause (or contributing cause) of end-stage renal disease in 5% of the European dialysis population. In these patients, bone lead levels were four times higher than in unexposed cadavers (6 micrograms/g wet weight) and approximated levels found in lead workers (30 micrograms/g). At present, the most reliable index of the body lead burden is the CaNa2 EDTA lead mobilization test. In vivo tibial X-ray-induced X-ray fluorescence (XRF) is a more practical noninvasive technique for assessing bone lead, which should find widespread application as a diagnostic tool and for epidemiologic studies. 1988-06 /pmc/articles/PMC1474623/ /pubmed/3203647 Text en |
spellingShingle | Research Article Wedeen, R P Bone lead, hypertension, and lead nephropathy. |
title | Bone lead, hypertension, and lead nephropathy. |
title_full | Bone lead, hypertension, and lead nephropathy. |
title_fullStr | Bone lead, hypertension, and lead nephropathy. |
title_full_unstemmed | Bone lead, hypertension, and lead nephropathy. |
title_short | Bone lead, hypertension, and lead nephropathy. |
title_sort | bone lead, hypertension, and lead nephropathy. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474623/ https://www.ncbi.nlm.nih.gov/pubmed/3203647 |
work_keys_str_mv | AT wedeenrp boneleadhypertensionandleadnephropathy |